Turn Therapeutics Inc. (TTRX) Stock

Turn Therapeutics Inc. (TTRX) is a Healthcare stock trading at $9.49 (as of 2026-08-21), with a market capitalization of $282.84M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Turn Therapeutics (Global Health Solutions, Inc.) develops pharmaceutical products for conditions of the skin, nails, and eye. Its products and delivery approach are used in wound care to address acute and chronic wounds and support antibiotic resistance reduction in clinical settings.

Understand Turn Therapeutics Inc.: how it makes money

Turn Therapeutics develops drugs to treat skin, nails, and eye diseases, using its delivery technology that penetrates skin and nails and is designed to reduce antibiotic resistance through acute and chronic wound care products sold to healthcare institutions.

Its profit model depends on whether its delivery technology and drug programs, such as GX-03, demonstrate clinically meaningful response rates in trials, because translating those interim efficacy results into approved therapies is what would enable future product revenue.

Business quality (Weak): The most actionable disclosed information is clinical-trial performance for specific endpoints (eczema response rates) and interim trial progress (completed subjects), but there is no segment revenue breakdown provided here.

Bull case

  • GX-03 shows stronger early efficacy than vehicle on the Week 4 50% endpoint: Eczema Area and Severity Index 50% Response Rate at Week 4 (GX-03) is 92.6%, compared with 65.2% for Vehicle.
  • Interim analysis has measurable trial progress: Number of Completed Subjects in Interim Analysis is 50.

Bear case

  • Results are endpoint-specific and may not persist or translate: The disclosed KPIs focus on particular response rates at Week 4 (and some Week 8/other thresholds), which may differ in later trials, additional time points, or broader patient populations.
  • Vehicle comparisons highlight placebo effects and uncertainty: Vehicle shows meaningful response rates on several endpoints, so interpreting GX-03 performance requires caution about how much effect is attributable to the active product versus study conditions.
Valuation — source: SEC EDGAR (first-party)
Price$9.49
Market Cap$282.84M
Price / Book411.77
Price / Sales4252.87
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$29583.00
Net Margin-10797.0%
Revenue Growth (YoY)861.8%
EPS Growth (YoY)200.0%
Financial Health — source: SEC EDGAR
Altman Z-Score18.46 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDDFG, Inc ($225709.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBradley E. Burnam
Employees2
CountryUS
IPO Date2025-10-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Cartesian Therapeutics, Inc. (RNAC)
  • Entrada Therapeutics, Inc. (TRDA)
  • Fulcrum Therapeutics, Inc. (FULC)
  • CAMP4 Therapeutics Corporation (CAMP)
  • Eledon Pharmaceuticals, Inc. (ELDN)
  • ALX Oncology Holdings Inc. (ALXO)
  • Zentalis Pharmaceuticals, Inc. (ZNTL)
  • Immuron Limited (IMRN)
TTRX earnings history · TTRX institutional & insider holders · TTRX KPIs & operating metrics · TTRX financials · TTRX investor presentations & press releases · TTRX SEC filings · TTRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.